Publicacións en colaboración con investigadores/as de Massachusetts General Hospital (5)

2024

  1. Capmatinib plus nazartinib in patients with EGFR-mutated non–small cell lung cancer

    European Journal of Cancer, Vol. 208

2023

  1. Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations

    Journal of Thoracic Oncology, Vol. 18, Núm. 11, pp. 1581-1593

2016

  1. Anti-tumor activity of PM01183 (lurbinectedin) in BRCA1/2-associated metastatic breast cancer patients: results of a single-agent phase II trial

    Annals of Oncology, Vol. 27, pp. vi68

2015

  1. Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer

    International Journal of Cancer, Vol. 136, Núm. 8, pp. 1863-1873

2014

  1. Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors

    Annals of Oncology, Vol. 25, Núm. 8, pp. 1656-1663